Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.
You may also be interested in...
Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data
Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.